Asset Details
Do you wish to reserve the book?
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Do you wish to request the book?
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
2020
Overview
Background and aims
Sodium–glucose linked cotransporter-2 (SGLT2) inhibitors reduce the likelihood of hospitalization for heart failure and cardiovascular death in both diabetic and non-diabetic individuals with reduced ejection fraction heart failure. Because SGLT2 inhibitors lead to volume contraction with reductions in both preload and afterload, these load-dependent factors are thought to be major contributors to the cardioprotective effects of the drug class. Beyond these effects, we hypothesized that SGLT2 inhibitors may also improve intrinsic cardiac function, independent of loading conditions.
Methods
Pressure–volume (P–V) relationship analysis was used to elucidate changes in intrinsic cardiac function, independent of alterations in loading conditions in animals with experimental myocardial infarction, a well-established model of HFrEF. Ten-week old, non-diabetic Fischer F344 rats underwent ligation of the left anterior descending (LAD) coronary artery to induce myocardial infarction (MI) of the left ventricle (LV). Following confirmation of infarct size with echocardiography 1-week post MI, animals were randomized to receive vehicle, or the SGLT2 inhibitor, empagliflozin. Cardiac function was assessed by conductance catheterization just prior to termination 6 weeks later.
Results
The circumferential extent of MI in animals that were subsequently randomized to vehicle or empagliflozin groups was similar. Empagliflozin did not affect fractional shortening (FS) as assessed by echocardiography. In contrast, load-insensitive measures of cardiac function were substantially improved with empagliflozin. Load-independent measures of cardiac contractility, preload recruitable stroke work (PRSW) and end-systolic pressure volume relationship (ESPVR) were higher in rats that had received empagliflozin. Consistent with enhanced cardiac performance in the heart failure setting, systolic blood pressure (SBP) was higher in rats that had received empagliflozin despite its diuretic effects. A trend to improved diastolic function, as evidenced by reduction in left ventricular end-diastolic pressure (LVEDP) was also seen with empagliflozin. MI animals treated with vehicle demonstrated myocyte hypertrophy, interstitial fibrosis and evidence for changes in key calcium handling proteins (all p < 0.05) that were not affected by empagliflozin therapy.
Conclusion
Empagliflozin therapy improves cardiac function independent of loading conditions. These findings suggest that its salutary effects are, at least in part, due to actions beyond a direct effect of reduced preload and afterload.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Animals
/ Benzhydryl Compounds - pharmacology
/ Calcium
/ Calcium Signaling - drug effects
/ Collagen
/ Diabetes
/ Diastole
/ Fibrosis
/ Heart Failure - drug therapy
/ Heart Failure - physiopathology
/ Heart failure reduced ejection fraction
/ Kinases
/ Medicine
/ Myocardial Infarction - complications
/ Myocardial Infarction - metabolism
/ Myocardial Infarction - physiopathology
/ Sodium-Glucose Transporter 2 Inhibitors - pharmacology
/ Sodium–glucose linked co-transporter 2 inhibitor
/ Software
/ Stroke Volume - drug effects
/ Systole
